AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12518121
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg t-PA (Group B)
Trial: 12518121
Drug: No thrombolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No thrombolytic therapy (Group C)
Trial: 9690729
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.d. + Amoxycillin 500 mg t.d.s. for 2 weeks (Study 1)
Trial: 9690729
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. + Amoxycillin 1 g t.d.s. for 2 weeks (Study 2)
Trial: 9690729
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. + Amoxycillin 1 g t.d.s. for 2 weeks (Study 3)
Trial: 9690729
Drug: Omeprazole monotherapy
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole monotherapy
Trial: 9690729
Drug: Amoxycillin monotherapy
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin monotherapy
Trial: 2698566
Drug: Gallopamil 25
RxNorm normalized name: gallopamil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil 25 mg
Trial: 2698566
Drug: Gallopamil 100
RxNorm normalized name: gallopamil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil 100 mg
Trial: 2698566
Drug: Nifedipine (Capsule)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Capsule) 5 mg
Trial: 2698566
Drug: Nifedipine (Capsule)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Capsule) 10 mg
Trial: 2698566
Drug: Nifedipine (Capsule)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Capsule) 20 mg
Trial: 2698566
Drug: Nifedipine (Tablet)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Tablet) 20 mg
Trial: 2698566
Drug: Nifedipine (Tablet)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Tablet) 40 mg
Trial: 2698566
Drug: Nifedipine (Tablet)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Tablet) 60 mg
Trial: 2698566
Drug: Tiapamil 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil 300 mg
Trial: 3539614
Drug: Tiapamil 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil 600 mg
Trial: 1093655
Drug: Ampicillin, 500
RxNorm normalized name: Ampicillin, 500 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin, 500 mg, 4 times daily for 10 days
Trial: 1093655
Drug: Trimethoprim-sulfamethoxazole, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole, 4 times daily for 10 days
Trial: 28560658
Drug: Pradefovir 90
RxNorm normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradefovir 90 mg
Trial: 28560658
Drug: Pradefovir 120
RxNorm normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradefovir 120 mg
Trial: 30576013
Drug: Vildagliptin-metformin combination
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin-metformin combination treatment
Trial: 30576013
Drug: Metformin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin monotherapy (standard-of-care)
Trial: 23438853
Drug: Morphine (0.08mg/kg)
RxNorm normalized name: morphine 0.23 MG
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (0.08mg/kg)
Trial: 14696021
Drug: Valerian 500
RxNorm normalized name: Valerian 500mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian 500 mg
Trial: 14696021
Drug: Valerian 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian 1000 mg
Trial: 10933133
Drug: Glibenclamide from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide from metformin/glibenclamide tablets
Trial: 3921585
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (20 cm2 patch)
Trial: 22623413
Drug: Oral alanyl-glutamine
RxNorm normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alanyl-glutamine (GLN) 25 g twice daily for 3 days preoperatively
Trial: 17514499
Drug: MF59‐adjuvanted subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59‐adjuvanted subunit vaccine (Sub/MF59)
Trial: 17383057
Drug: Conventional subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional subunit vaccine (Subunit)
Trial: 11436117
Drug: G‐CSF 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 6 microg/kg/day s.c.
Trial: 7544174
Drug: Alpha 1-blockers
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha 1-blockers
Trial: 7544174
Drug: 5 alpha-reductase
RxNorm normalized name: 5.alpha.-hydroxy laxogenin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 alpha-reductase inhibitors
Trial: 2527819
Drug: ANF infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANF infusion (0.75 pmol/kg/min for 3 hours)
Trial: 23648392
Drug: Need-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Need-based intervention (50g/day soy-protein-based nutritional supplement)
Trial: 21710480
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml butyl‐2‐cyanoacrylate tissue glue (Glubran(®))
Trial: 15587751
Drug: Calcitriol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.5 microg/day) and calcium (1000 mg/day)
Trial: 15587751
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg/day) alone
Trial: 11502785
Drug: GH administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH administration (20 microg/kg BW)
Trial: 11502785
Drug: Sex hormone
RxNorm normalized name: Sex hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormone administration (hormone replacement therapy in women, testosterone enanthate in men)
Trial: 11502785
Drug: GH administration,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH administration, testosterone enanthate, GH + testosterone enanthate
Trial: 9426995
Drug: Ciprofloxacin 1
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1 g (CIP1)
Trial: 9426995
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg b.i.d. for 1 day (CIP2)
Trial: 9426995
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg b.i.d. for 3 days (D)
Trial: 8296092
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR vaccine (5 x 10^9 FU)
Trial: 30150192
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder (GP) at a dose rate of 2 g/day
Trial: 30150192
Drug: Coriander seed
RxNorm normalized name: coriander seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coriander seed powder (CSP) at a dose rate of 2 g/day
Trial: 30150192
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of garlic powder and coriander seed powder (1:1 dry weight basis) at a dose rate of 2 g/day
Trial: 17725303
Drug: Vardenafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (10 mg to 20 mg for 2 months)
Trial: 17725303
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg daily for 2 months)
Trial: 15470715
Drug: Sequential irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential irinotecan plus bolus 5‐FU/LV (Arm B)
Trial: 8914949
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil capsules containing 1.5-1.8 g of DHA
Trial: 8914949
Drug: Control oil
RxNorm normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control oil capsules containing 97% soybean oil and 3% fish oil
Trial: 31477161
Drug: Febuxostat 20
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 20 mg daily
Trial: 31477161
Drug: Benzbromarone 25
RxNorm normalized name: benzbromarone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzbromarone 25 mg daily
Trial: 16982294
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg QD for 5 days
Trial: 16982294
Drug: Amoxicillin/clavulanate 875
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate 875 mg/125 mg BID for 10 days
Trial: 9333066
Drug: Cefodizime (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefodizime (single 2‐g intravenous dose)
Trial: 9333066
Drug: Ceftriaxone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (single 2‐g intravenous dose)
Trial: 8265839
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg q.d.s.)
Trial: 8265839
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (10 mg q.d.s.)
Trial: 26321218
Drug: Inhaled Alpha‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Alpha‐1 HC 100 mg
Trial: 26321218
Drug: Inhaled Alpha‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Alpha‐1 HC 200 mg
Trial: 23890273
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Pegylated interferon (160 μg weekly) + Ribavirin (1200 mg if ≥ 75 kg, 1000 mg if <75 kg) for 48 weeks
Trial: 23890273
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Nitazoxanide (500 mg bid for 4 weeks lead-in) + Pegylated interferon + Ribavirin for 48 weeks
Trial: 16599102
Drug: Intensive nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive nutrition education (INE) twice a week for three months
Trial: 16599102
Drug: Intensive nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive nutrition education with supplementary feeding (INE+SF) twice a week for three months
Trial: 16599102
Drug: Standard routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard routine nutrition education from community nutrition promoters twice a month
Trial: 9732938
Drug: Dual therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy: Lansoprazole (30 mg b.i.d.) and Amoxicillin (1 g b.i.d.)
Trial: 9732938
Drug: Triple therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy: Lansoprazole (30 mg b.i.d.), Amoxicillin (1 g b.i.d.), and Clarithromycin (500 mg b.i.d.)
Trial: 2525998
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg + Hydrochlorothiazide 25 mg (group A)
Trial: 2525998
Drug: Amiloride 5
RxNorm normalized name: amiloride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 5 mg + Hydrochlorothiazide 50 mg (group B)
Trial: 8803642
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (enoxaparin 40 mg once daily)
Trial: 8803642
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg once daily) plus graduated elastic compression (TEDR stockings) for 8-12 days
Trial: 1387231
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g fish oil preparation
Trial: 1387231
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g fish oil preparation
Trial: 1387231
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g fish oil preparation
Trial: 1387231
Drug: Both fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both fish oil preparations
Trial: 6436897
Drug: Haloperidol 16
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 16 mg per day (low dose)
Trial: 6436897
Drug: Haloperidol 80
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 80 mg per day (high dose)
Trial: 29423774
Drug: Glucose levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose levels above the median (11.5 mmol/L)
Trial: 26616224
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 administered over a 3 hour infusion, cycling every 21 days
Trial: 18619799
Drug: Dietary fiber
RxNorm normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fiber therapy
Trial: 8910627
Drug: Any antigen
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any antigen preparation
Trial: 8910627
Drug: High antibody
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antibody titers
Trial: 6873561
Drug: Propantheline bromide
RxNorm normalized name: Propantheline Bromide
DrugBank: Propantheline (DB00782)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propantheline bromide (anticholinergic agent)
Trial: 2579597
Drug: Intraderma injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraderma injection of terbutaline (0.25-100 ng)
Trial: 2579597
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline and theophylline treatment
Trial: 22849416
Drug: Blind lineup
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind lineup administration (presumed blind condition)
Trial: 22849416
Drug: Non-blind lineup
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-blind lineup administration (presumed nonblind condition)
Trial: 14520027
Drug: Fat-modified diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-modified diet with caloric restriction and daily intake of 35-50 g oat bran
Trial: 10655911
Drug: Propofol 3-4
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 3-4 mg kg-1 with succinylcholine 2 mg kg-1
Trial: 8887260
Drug: Prednisolone in
RxNorm normalized name: methylprednisolone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone in combination with other immunosuppressants
Trial: 8887260
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment protocols
Trial: 1649265
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with cyclophosphamide, doxorubicin, and vincristine (CAV)
Trial: 26391623
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (AADs), n = 5
Trial: 26391623
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic drugs (AADs), n = 8
Trial: 21663809
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (50 mg)
Trial: 19636011
Drug: rhITF 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhITF 10 mg/mL (low dose)
Trial: 19636011
Drug: rhITF 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhITF 80 mg/mL (high dose)
Trial: 15288082
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 30% saccharose solution with non nutritive pacifier sucking (S)
Trial: 15288082
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 30% saccharose solution with local application of Emla and with non nutritive pacifier sucking (S + E)
Trial: 8164926
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined regimen with 2.5 mg of MPA (Group A)
Trial: 8164926
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined regimen with 5.0 mg of MPA (Group B)
Trial: 8164926
Drug: Sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen with 5.0 mg of MPA (Group C)
Trial: 8164926
Drug: Sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen with 10.0 mg of MPA (Group D)
Trial: 26293750
Drug: Fewer drug-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fewer drug-related problems
Trial: 26293750
Drug: No use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No use of hard drugs within the prior 30 days
Trial: 25601341
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (1000 mg once daily) plus prednisone (5 mg twice daily)
Trial: 20233897
Drug: 7.5% CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% CO2 inhalation for 20 minutes
Trial: 20233897
Drug: 7.5% CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% CO2 inhalation on day 2
Trial: 16820555
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol (1 to 3 mg/h for 48 hours)
Trial: 16820555
Drug: Oral metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoprolol (25 mg twice per day to 50 mg 3 times per day starting on the first postoperative morning)
Trial: 10849056
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of lansoprazole (30 mg once daily), clarithromycin (250 mg twice daily), and amoxicillin (500 mg three times daily)
Trial: 10849056
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of lansoprazole (30 mg once daily), clarithromycin (250 mg twice daily), and amoxicillin (500 mg three times daily)
Trial: 27365164
Drug: Capillary drug
RxNorm normalized name: Artemisia capillaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capillary drug concentrations after administration of a single dose of antipsychotic drugs
Trial: 27365164
Drug: Venous drug
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venous drug concentrations after administration of a single dose of antipsychotic drugs
Trial: 22963750
Drug: G-CSF/CPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF/CPC
Trial: 18476965
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral sildenafil 100 mg (group III)
Trial: 18476965
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral sildenafil 25 mg (group II)
Trial: 18476965
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection (ICI) with PGE1 (5 microg) and oral sildenafil 100 mg (group V)
Trial: 18476965
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection (ICI) with PGE1 (5 microg) and oral placebo (group IV)
Trial: 18476965
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral placebo (group I)
Trial: 29161349
Drug: Lutein and
RxNorm normalized name: ICaps Lutein and Omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein and zeaxanthin (L&Z)
Trial: 17313848
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (tacrolimus + glucocorticoid)
Trial: 17313848
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (tacrolimus + mycophenolate mofetil + glucocorticoid)
Trial: 17313848
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (tacrolimus + mycophenolate mofetil + glucocorticoid + daclizumab)